Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Incorporated (Nasdaq: INSM) announced that it has granted inducement awards to 24 new employees as part of their employment offer.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Very Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) announced that it has granted inducement awards to 24 new employees as part of their employment offer. The approved awards, compliant with NASDAQ Listing Rule 5635(c)(4), include options to purchase 158,530 shares of common stock at an exercise price of $17.93 per share, equivalent to the closing price on June 1, 2022. The options have a 10-year term and a four-year vesting schedule. Insmed is focused on therapies for serious and rare diseases, with a strong commitment to enhancing patient lives.

Positive

Granting options encourages employee retention and aligns interests with shareholders.
Inducement awards may enhance the company's ability to attract talent.

Negative

None.

Argus Session date unavailable

+5.91% session move Open Argus

Details

News Market Reaction – INSM

The recorded move for INSM in the trading session of this news was +5.91%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

06/03/2022 - 08:00 AM

BRIDGEWATER, N.J., June 3, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 24 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

In connection with the commencement of their employment, the employees received options on June 1, 2022 to purchase an aggregate 158,530 shares of Insmed common stock at an exercise price of $17.93 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com

Media:

Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301560379.html

SOURCE Insmed Incorporated

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement awards did Insmed grant to new employees?

Insmed granted options to purchase 158,530 shares of common stock at an exercise price of $17.93 to 24 new employees.

What is the term and vesting schedule of the options granted by Insmed?

The options have a 10-year term and a four-year vesting schedule.

Under which NASDAQ rule did Insmed grant the inducement awards?

The inducement awards were granted in accordance with NASDAQ Listing Rule 5635(c)(4).

When were the stock options granted by Insmed?

The stock options were granted on June 1, 2022.

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)